Bailard’s Myriad Genetics MYGN Stock Holding History

Bailard’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,000	Closed	-$219K	–	797
2024 Q3	$219K	Buy	+8,000	New	+$217K	0.01%	688

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bailard's MYGN Position: Q4 2024 in Review

Bailard sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 8,000 shares — an estimated $219K sold.

Bailard first reported a position in MYGN in Q3 2024 and held it in 1 quarter. The position peaked at $219K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

Bailard reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
Bailard sold 8,000 Myriad Genetics shares in Q4 2024, an estimated $219K.
Bailard first reported a position in Myriad Genetics in Q3 2024 and held it in 1 quarter.
Bailard's Myriad Genetics position peaked at $219K in Q3 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Bailard's 13F filing for Q4 2024, filed 5 Feb 2025.